(Reuters) – Ionis Pharmaceuticals said on Wednesday its experimental drug to treat a type of fatty liver disease met the main goal of a mid-stage trial.
The drug candidate, called ION224, was tested in a 160-patient study for 51 weeks, and helped improve symptoms of the disease in both tested doses.
The condition, earlier called non-alcoholic steatohepatitis (NASH), has no approved drugs, with the U.S. Food and Drug Administration expected to decide on rival Madrigal Pharmacauticals’ drug by Thursday.
(Reporting by Pratik Jain in Bengaluru; Editing by Savio D’Souza and Sriraj Kalluvila)
